<DOC>
	<DOCNO>NCT00463606</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ABT-335 rosuvastatin calcium combination therapy monotherapy subject dyslipidemia .</brief_summary>
	<brief_title>A Multicenter Study Comparing Safety Efficacy ABT-335 Rosuvastatin Calcium Combination Therapy Monotherapy Subjects With Dyslipidemia</brief_title>
	<detailed_description>There 3 treatment group study : ABT-335 135 mg combination rosuvastatin 5 mg , ABT-335 135 mg monotherapy , rosuvastatin 5 mg monotherapy . The 3 primary outcome measure compare 2 treatment group variable ( mean percent change HDL-C TG compare ABT-335 135 mg combination rosuvastatin 5 mg rosuvastatin 5 mg monotherapy , mean percent change LDL-C compare ABT-335 135 mg combination rosuvastatin 5 mg ABT-335 135 mg monotherapy . The 6 secondary outcome measure compare 2 treatment group variable ( mean percent change Non-HDL-C compare ABT-335 135 mg combination rosuvastatin 5 mg ABT-335 135 mg monotherapy , mean percent change Non-HDL-C , VLDL-C , ApoB , Total Cholesterol compare ABT-335 135 mg combination rosuvastatin 5 mg rosuvastatin 5 mg monotherapy , median percent change hsCRP compare ABT-335 135 mg combination rosuvastatin 5 mg rosuvastatin 5 mg monotherapy ) .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Inclusion Criteria Adult male female participant voluntarily sign informed consent . Fasting lipid result follow great 12hour fasting period : Triglycerides level great equal 150 mg/dL , Highdensity lipoprotein cholesterol le 40 mg/dL male less 50 mg/dL female , Lowdensity lipoprotein cholesterol great equal 130 mg/dL . Participant must agree utilize adequate birth control method adhere American Heart Association ( AHA ) diet . Exclusion Criteria Participants unstable medical condition , medical condition consider inappropriate clinical trial , participant take exclude concomitant medication allow study . Participants receive coumarin anticoagulant systemic cyclosporine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>